Q2 2025 Earnings Call Transcript August 1, 2025 Fulgent Genetics, Inc. misses on earnings expectations. Reported EPS is $-0.62065 EPS, expectations were $-0.23. Operator: Greetings, and welcome to the ...

Fulgent Genetics Inc (FLGT) reports a 16% increase in core revenue and expands market reach, despite facing GAAP losses and ...

Fulgent Genetics (FLGT) delivered earnings and revenue surprises of +130.43% and +7.80%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

That was accompanied by a double-digit improvement in revenue.

Fulgent Genetics ranks at the bottom for Revenue Growth and Gross Profit, with negative percentages. It is also at the bottom for Return on Equity, with a negative percentage. Overall, Fulgent ...

Arc Resources 2Q EPS C$0.68; 2Q Net C$396.1M; 2Q Avg Production 357,228 BOE/Day; 2Q Funds From Operations C$682M, or C$1.17/Share; Boosts 2025 Capital Spending Plan to C$1.85B-C$1.95B; Sees 2025 ...

Get the cash flow statement for Fulgent Genetics, Inc. (FLGT). Up to 10 years of financial statements. Quarterly or annual. View as % YoY growth or as % of revenue.

FulgentExome is a patient-centric, phenotype-driven analysis designed to examine coding regions and splice junctions for more than 4600 genes and to report only the variants, which are of plausible ...

EL MONTE, Calif., July 17, 2025--Fulgent Genetics, Inc. (NASDAQ: FLGT) ("Fulgent," or the "Company"), a technology-based company with a well-established laboratory services business and a ...

Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent,” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business ...